Organon & Co. reported full year (FY) 2025 revenue of USD 6.2 billion, representing a decline of 3%. Diluted earnings per share for FY 2025 were USD 0.72, while non-GAAP adjusted diluted earnings per share were USD 3.66. Adjusted EBITDA for the year reached USD 1.91 billion, including USD 6 million of IPR&D, with an adjusted EBITDA margin of 30.7%. For the geographic breakdown, FY 2025 sales were USD 1.62 billion in Europe and Canada, USD 1.60 billion in the United States, USD 1.00 billion in Asia Pacific and Japan, USD 0.83 billion in China, and USD 1.07 billion in Latin America, Middle East, Russia, and Africa. Management highlighted actions taken in 2025 to improve the balance sheet and build greater financial flexibility. Organon & Co. expects to deliver approximately USD 6.2 billion of revenue and around USD 1.9 billion of adjusted EBITDA for full year 2026, in line with FY 2025 performance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organon & Co. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260212249326) on February 12, 2026, and is solely responsible for the information contained therein.